Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia.

Baheti T, Nischal A, Nischal A, Khattri S, Arya A, Tripathi A, Pant KK.

Schizophr Res. 2013 Jun;147(1):201-2. doi: 10.1016/j.schres.2013.03.017. Epub 2013 Apr 11. No abstract available.

PMID:
23582654
2.

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.

Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Möller HJ, Klauss V, Schwarz MJ, Riedel M.

Schizophr Res. 2010 Aug;121(1-3):118-24. doi: 10.1016/j.schres.2010.04.015. Epub 2010 May 31.

PMID:
20570110
3.

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ.

Am J Psychiatry. 2002 Jun;159(6):1029-34.

PMID:
12042193
4.

Celecoxib augmentation of continuously ill patients with schizophrenia.

Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D.

Biol Psychiatry. 2005 Jun 15;57(12):1594-6.

PMID:
15953498
5.

Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.

Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, Hassanzadeh E, Forghani S, Akhondzadeh S.

Psychopharmacology (Berl). 2013 Jan;225(1):51-9. doi: 10.1007/s00213-012-2796-8. Epub 2012 Jul 11.

PMID:
22782459
6.

COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.

Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, Riedel M.

Eur Arch Psychiatry Clin Neurosci. 2004 Feb;254(1):14-22.

PMID:
14991374
7.

Clinical effects of COX-2 inhibitors on cognition in schizophrenia.

Müller N, Riedel M, Schwarz MJ, Engel RR.

Eur Arch Psychiatry Clin Neurosci. 2005 Apr;255(2):149-51. Epub 2004 Nov 19.

PMID:
15549344
8.

Neurologic soft signs and olanzapine treatment in chronic schizophrenia.

Sevincok L, Topaloglu B, Kiyilioglu N.

J Clin Psychopharmacol. 2004 Oct;24(5):571-2. No abstract available.

PMID:
15349026
9.

Effects of olanzapine on the PR and QT intervals in patients with schizophrenia.

Suzuki Y, Ono S, Tsuneyama N, Sawamura K, Sugai T, Fukui N, Watanabe J, Someya T.

Schizophr Res. 2014 Jan;152(1):313-4. doi: 10.1016/j.schres.2013.10.036. Epub 2013 Nov 23. No abstract available.

PMID:
24275577
10.

Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment.

Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V, Müller N.

J Affect Disord. 2011 Nov;134(1-3):217-25. doi: 10.1016/j.jad.2011.05.047. Epub 2011 Jun 17.

PMID:
21684012
11.

Improvement of thyroid eye disease following treatment with the cyclooxygenase-2 selective inhibitor celecoxib.

Kuriyan AE, Phipps RP, O'Loughlin CW, Feldon SE.

Thyroid. 2008 Aug;18(8):911-4. doi: 10.1089/thy.2007.0325. No abstract available.

12.

Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.

Narendran R, Young CM, Valenti AM, Pristach CA, Pato MT, Grace JJ.

J Clin Psychiatry. 2001 Jul;62(7):509-16.

PMID:
11488360
13.

Inflammatory pathogenesis of prostate cancer and celecoxib.

Mathew P.

J Clin Oncol. 2010 Apr 20;28(12):e197; author reply e198. doi: 10.1200/JCO.2009.27.1098. Epub 2010 Feb 22. No abstract available.

PMID:
20177014
14.

Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode.

Peuskens J, Kaufman L, Van Vleymen B.

Schizophr Res. 2007 Sep;95(1-3):169-73. Epub 2007 Jul 13.

PMID:
17630255
15.

Celecoxib-induced bullous pemphigoid.

Apap C, Boffa MJ, Cordina J.

Skinmed. 2013 May-Jun;11(3):190-1. No abstract available.

PMID:
23930364
16.

Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.

Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.

J Clin Psychiatry. 2008 Dec;69(12):1901-15. Epub 2008 Sep 9.

PMID:
19012820
17.

Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.

Hatta K, Otachi T, Fujita K, Morikawa F, Ito S, Tomiyama H, Abe T, Sudo Y, Takebayashi H, Yamashita T, Katayama S, Nakase R, Shirai Y, Usui C, Nakamura H, Ito H, Hirata T, Sawa Y; JAST study group..

Schizophr Res. 2014 Sep;158(1-3):213-22. doi: 10.1016/j.schres.2014.07.015. Epub 2014 Jul 31.

18.

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.

Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B.

Schizophr Res. 2007 Feb;90(1-3):179-85. Epub 2007 Jan 8.

PMID:
17208413
19.

Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.

Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC.

Hum Psychopharmacol. 2008 Mar;23(2):87-94. doi: 10.1002/hup.912.

PMID:
18172906
20.

Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing.

Gómez de la Fuente E, Pampín Franco A, Caro Gutiérrez D, López Estebaranz JL.

Actas Dermosifiliogr. 2014 Apr;105(3):314-5. doi: 10.1016/j.adengl.2013.04.022. Epub 2014 Mar 21. No abstract available.

PMID:
24661957

Supplemental Content

Support Center